Breast cancer immunotherapy: Facts and hopes

Leisha A. Emens

Research output: Contribution to journalReview article

Abstract

Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 (PD-1/ PD-L1) antagonists in small numbers of patients with metastatic breast cancer. Clinical activity appears more likely if the tumor is triple negative, PD-L1þ, and/or harbors higher levels of tumor-infiltrating leukocytes. Responses to atezolizumab and pembrolizumab appear to be durable in metastatic triple-negative breast cancer (TNBC), suggesting that these agents may transform the lives of responding patients. Current clinical efforts are focused on developing immunotherapy combinations that convert nonresponders to responders, deepen those responses that do occur, and surmount acquired resistance to immunotherapy. Identifying biomarkers that can predict the potential for response to single-agent immunotherapy, identify the best immunotherapy combinations for a particular patient, and guide salvage immunotherapy in patients with progressive disease are high priorities for clinical development. Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.

Original languageEnglish (US)
Pages (from-to)511-520
Number of pages10
JournalClinical Cancer Research
Volume24
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Immunotherapy
Breast Neoplasms
CD274 Antigen
Biomarkers
Triple Negative Breast Neoplasms
Neoplasms
Leukocytes
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Breast cancer immunotherapy : Facts and hopes. / Emens, Leisha A.

In: Clinical Cancer Research, Vol. 24, No. 3, 01.02.2018, p. 511-520.

Research output: Contribution to journalReview article

Emens, Leisha A. / Breast cancer immunotherapy : Facts and hopes. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 3. pp. 511-520.
@article{714fce9aedce4ad384ae741150bc9ead,
title = "Breast cancer immunotherapy: Facts and hopes",
abstract = "Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 (PD-1/ PD-L1) antagonists in small numbers of patients with metastatic breast cancer. Clinical activity appears more likely if the tumor is triple negative, PD-L1{\th}, and/or harbors higher levels of tumor-infiltrating leukocytes. Responses to atezolizumab and pembrolizumab appear to be durable in metastatic triple-negative breast cancer (TNBC), suggesting that these agents may transform the lives of responding patients. Current clinical efforts are focused on developing immunotherapy combinations that convert nonresponders to responders, deepen those responses that do occur, and surmount acquired resistance to immunotherapy. Identifying biomarkers that can predict the potential for response to single-agent immunotherapy, identify the best immunotherapy combinations for a particular patient, and guide salvage immunotherapy in patients with progressive disease are high priorities for clinical development. Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.",
author = "Emens, {Leisha A.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-16-3001",
language = "English (US)",
volume = "24",
pages = "511--520",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Breast cancer immunotherapy

T2 - Facts and hopes

AU - Emens, Leisha A.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 (PD-1/ PD-L1) antagonists in small numbers of patients with metastatic breast cancer. Clinical activity appears more likely if the tumor is triple negative, PD-L1þ, and/or harbors higher levels of tumor-infiltrating leukocytes. Responses to atezolizumab and pembrolizumab appear to be durable in metastatic triple-negative breast cancer (TNBC), suggesting that these agents may transform the lives of responding patients. Current clinical efforts are focused on developing immunotherapy combinations that convert nonresponders to responders, deepen those responses that do occur, and surmount acquired resistance to immunotherapy. Identifying biomarkers that can predict the potential for response to single-agent immunotherapy, identify the best immunotherapy combinations for a particular patient, and guide salvage immunotherapy in patients with progressive disease are high priorities for clinical development. Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.

AB - Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 (PD-1/ PD-L1) antagonists in small numbers of patients with metastatic breast cancer. Clinical activity appears more likely if the tumor is triple negative, PD-L1þ, and/or harbors higher levels of tumor-infiltrating leukocytes. Responses to atezolizumab and pembrolizumab appear to be durable in metastatic triple-negative breast cancer (TNBC), suggesting that these agents may transform the lives of responding patients. Current clinical efforts are focused on developing immunotherapy combinations that convert nonresponders to responders, deepen those responses that do occur, and surmount acquired resistance to immunotherapy. Identifying biomarkers that can predict the potential for response to single-agent immunotherapy, identify the best immunotherapy combinations for a particular patient, and guide salvage immunotherapy in patients with progressive disease are high priorities for clinical development. Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85041032773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041032773&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-3001

DO - 10.1158/1078-0432.CCR-16-3001

M3 - Review article

C2 - 28801472

AN - SCOPUS:85041032773

VL - 24

SP - 511

EP - 520

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -